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Background: Melphalan resistance has been considered one of the major obstacles to improve outcomes in
multiple myeloma (MM) therapy; unfortunately, the mechanistic details of this resistance remain unclear. Melphalan
is a highly effective alkylating agent which causes many types of DNA lesions, including DNA base alkylation
damage that is repaired by base excision repair (BER). We postulated that human apurinic/apyrimidinic
endonuclease 1 (APE1), an essential BER enzyme, plays a vital role in acquired melphalan resistance. However,
because APE1 is a multifunctional protein with redox activity and acetylation modification in addition to its major
repair activity, the particular APE1 function that may play a more important role in melphalan resistance is unknown.
Methods: Two MM cell lines, RPMI-8226 and U266 were used to measure the difference in APE1 levels in
melphalan-resistant and sensitive derivatives. APE1 functional mutants for DNA repair, redox and acetylation were
employed to investigate the roles of individual APE1 activities in acquired melphalan resistance.
Results: Our results indicate that APE1 is overexpressed in both MM melphalan-resistant cells. Knocking down APE1
sensitizes the melphalan resistant MM cells to melphalan treatment. The exogenous expression of DNA repair
mutant H309N and acetylation mutant K6R/K7R of APE1 failed to restore the melphalan resistance of the APE1
knockdown RPMI-8226 cells. The AP endonuclease activity and multidrug resistance protein 1 (MDR1) regulatory
activity may play roles in the melphalan resistance of MM cells.
Conclusions: The present study has identified that the DNA repair functions and the acetylation modification of
APE1 are involved in melphalan resistance of MM cells and has also shed light on future therapeutic strategies
targeting specific APE1 functions by small molecule inhibitors.
Keywords: Acquired melphalan resistance, Multiple myeloma, Human apurinic/apyrimidinic endonuclease 1,
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Primary drug resistance in multiple myeloma (MM) pa-
tients has created a hurdle to consistently successful che-
motherapeutic outcomes. Despite gradual advances in
treatment using optimized strategies that combine multiple
agents, effective remission is achieved in a sub-optimal
number of patients (fewer than 50% of patients) [1]. The* Correspondence: xiejia505@sina.com
†Equal contributors
1Cancer Center, Research Institute of Surgery, Daping Hospital, Third Military
Medical University, Chongqing 400042, P.R China
Full list of author information is available at the end of the article
© 2014 Xie et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orcurrent standard of care for elderly MM patients includes
the nitrogen mustard alkylating agent melphalan in con-
junction with prednisone. Melphalan primarily distorts the
DNA guanine base with an alkyl group monoadduct [2],
particularly at the nitrogen atom 7 of the imidazole ring,
and it can also distort DNA with other adducts. Several
suspected means of in vitro resistance to these mustard
agents include cytokine production defects in the bone
marrow milieu, altered drug delivery by transporters that
effectively decrease cellular drug absorption, and an in-
crease in effective DNA repair of mustard-specific lesions
[3,4]. Currently it is unclear which of these pathways. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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regimens.
Among all the previously-proposed mechanistic
models, enhanced DNA repair capacity has been closely
associated to melphalan resistance in MM patients [5,6].
DNA repair function has been widely accepted as the
most important mechanism of resistance to anticancer
drugs, especially those specifically targeting DNA. Al-
though there are 5–6 major DNA repair pathways, the
major type of DNA damage caused by melphalan is base
alkylation which is mainly repaired by DNA base exci-
sion repair (BER) mechanisms [7]. Melphalan-induced
alkylated bases are recognized and removed by particular
glycosylases such as methylpurine glycosylase (MPG) leav-
ing an abasic site with the N-glycosyl bond intact. Then hu-
man apurinic/apyrimidinic endonuclease 1 (APE1) cleaves
the DNA backbone at the abasic site, leaving an exposed 3′
OH and 5′ deoxyribose phosphate. Following the function
of APE1, DNA polymerase beta incorporates the correct
nucleotide followed by nick ligation by ligase III. In the
BER pathway, the activity of APE1 largely determines the
effectiveness of this DNA repair [8]. APE1 is an essential
protein for many cellular processes [9] and its biological
importance is highlighted by early embryonic lethality in
mouse Apex1, the homologue of human APE1, knockout
mice [10]. A number of preclinical functional studies re-
vealed that APE1 is more highly expressed in various types
of tumor tissues which supposedly contributes to cancer
cell survival and proliferation [11,12]. Moreover, overex-
pression of APE1 in tumor tissues is usually closely corre-
lated with a less effective response or resistance to cancer
therapeutic agents [13,14]. Although the role of APE1 in
drug resistance has been established and widely accepted,
the detailed mechanisms for individual therapeutic agents
may vary and are not yet fully understood.
We previously reported that APE1 is involved in melpha-
lan resistance in the MM cell line KM3 by using a tissue-
specific inducible APE1 silencing vector [15]. As a result,
we confirmed that APE1 is a promising therapeutic target
and that suppressing the expression of APE1 might en-
hance melphalan treatment in MM patients. However,
APE1 is a multifunctional protein with at least two distinct
activities which play different roles in drug resistance. As
mentioned above, APE1 is the essential enzyme of DNA
base excision repair [16]. On the other hand, APE1 is a
redox factor regulating important agents involved in oxida-
tive stress, including NF-κB, AP-1, p53, and Egr-1 [17].
Notably, recent studies indicate a novel role of APE1 in
regulating MDR1 expression through an acetylation-
dependent mechanism [18]. The membrane-associated
protein encoded by the Mdr-1 gene is a member of the
superfamily of ATP-binding cassette (ABC) transporters
which functions as an ATP-dependent drug efflux pump
for xenobiotic compounds [19]. Therefore, it is responsiblefor decreased drug accumulation in multidrug-resistant cells
which further facilitates the development of drug resistance.
Taken together, overexpression of APE1 in MM cells
promotes resistance to melphalan, possibly through dif-
ferent mechanisms, while the involvement of different
activities of APE1 in this process remains unknown.
Therefore, we initiated the present study to explore
which APE1 functions are involved in melphalan resist-
ance in MM cells. We utilized APE1 overexpression or
RNAi vectors to measure the impact of manipulating
APE1 on melphalan resistance of the MM cell lines.
Additionally, we used APE1 function-specific or post-
transcriptional modification site mutant overexpression
vectors to differentiate the impact of specific APE1 activ-
ities on melphalan resistance. Our results indicated that
APE1 overexpression and manipulation in melphalan re-
sistant MM cells affects melphalan resistance. The DNA
repair activity and MDR1 regulatory activity of APE1 are
mainly involved in the melphalan resistance of RPMI-
8226 MM cells while DNA repair activity is more im-
portant in cell survival following melphalan treatment.
Methods
Cell and reagents
RPMI 1640 medium, Opti-MEM® I Reduced-Serum
Medium and fetal bovine serum, Lipofectamine™ 2000
Transfection Reagent, TRIzol RNA isolation reagent
and primers were from Invitrogen (Grand Island, NY).
Cell Counting Kit-8 (CCK-8), melphalan, myrecitin,
synthetic siRNA against APE1 and MDR1 were from
Sigma-Aldrich (St Louis, MO). Tetrahydrofuran-containing
oligonucleotides, biotin-conjugated oligos and all other
regular oligos were synthesized from Takara (Dalian,
China). T4 polynucleotide kinase (T4 PNK), T4 ligase,
restriction endonucleases, and high-fidelity Pfu DNA
polymerase were from Promega (Madison, WI). Halt
protease inhibitor cocktail, LightShift chemiluminescent
EMSA kit, Super Signal West Pico chemiluminescent
reagents, horseradish peroxidase-conjugated anti-mouse
or anti-rabbit IgG antibodies were from Pierce (Rockford,
IL). The chemo-sensitive RPMI-8226 and U266 cell line
were purchased from American Type Culture Collection
(Manassas, VA) and their melphalan-resistant sublines
RPMI-8226/LR5 and U266/LR6 were obtained from
Dr. William S. Dalton (Lee Moffitt Cancer Center, Tampa,
FL). All MM cell lines were grown in RPMI 1640 medium
supplemented with 10% fetal bovine serum, 100 U/ml
penicillin and 100 μg/ml streptomycin (Hyclone, Logan,
UT), and maintained at 37°C in a humidified atmosphere
in the presence of 5% CO2-95% air.
Constructs and transfection
The constructs of APE1 knockdown and wildtype or over-
expression mutants used in this study included pTer/
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p3XFLAG-CMV/APE1H309N (APE1H309N), p3XFLAG-CMV/
APE1C65S (APE1C65S), and p3XFLAG-CMV/APE1K6R/K7R
(APE1 K6R/K7R), kind gifts from Dr. Gianluca Tell (University
of Udine, Udine, Italy). The APE1 eukaryotic overexpression
vector was constructed based on the pcDNA-3.1 vector.
The detailed procedures were reported previously [9,20].
The transfections were performed using Lipofectamine™
2000 Transfection Reagent following the manufacturer’s
protocol for transient transfection of suspension cells.
CCK-8 assay
Cells (2 × 105) on 6-well plates were transfected or
treated as indicated. Cell viability was evaluated by MTT
assay at various time points after transfection or treat-
ment. Cell-counting kit-8 reagent was added to each
dish at a concentration of 1/10 volume, and the plates
were incubated at 37°C for an additional 4 h. Absorb-
ance was then measured at 490 nm and at 630 nm as a
reference with a Microplate Reader 550 (Bio-Rad La-
boratories, Hercules, CA). Cell viability (%) = OD value
of treatment group/OD value of control group × 100%.
Western blot and antibodies
Western blots were performed as previously described
[21]. Suppliers and incubation conditions of antibodies
used for Western blots were as follows: anti-APE1 mono-
clonal (Novus), 1 h at 37°C, dilution 1:5000; anti-MDR1
monoclonal (Sigma), dilution 1:500; HRP-conjugated anti-
acetylation lysine antibody (Milipore), dilution 1:1000,
overnight at 4°C; anti-β-actin monoclonal (Sigma), 1 h at
37°C, dilution 1:2000.
Quantitative RT-PCR
Expression of the APE1 gene was detected by real-time
RT-PCR and normalized by control gene β-actin expres-
sion. Total RNA was extracted using the TRIZOL re-
agent and then reverse-transcribed into single-stranded
DNA using PrimeScript™ 1st Strand cDNA Synthesis Kit
(Takara, Dalian, China). Real-time RT-PCR was per-
formed with a Lightcycler 480 real-time RT-PCR system
(Roche Diagnostics). APE1 forward primer, 5′-TGGA




The AP endonuclease activity of APE1 was evaluated by
a well-characterized oligonucleotide cleavage assay [21].
Briefly, a 51-mer oligonucleotide containing a THF site,
the analogue of an abasic site, at the 22nd position was
5′-end radiolabeled. The labeling reaction consisted of
10 pmol of the single stranded oligonucleotide, 2.5 pmol
of γ32P-ATP, T4 PNK, and appropriate kinase buffer in atotal volume of 10 μl. Reactants were incubated for
30 minutes at 37°C and 5 minutes at 95°C. Complemen-
tary oligonucleotide was then added and cooled down to
22°C to form duplex DNA. Activity assays contained 0.5
pmol of labeled duplex oligonucleotide, 1 × REC Buffer
[50 mM HEPES, 50 mM KCl, 10 mM MgCl2, 1% (w/v)
bovine serum albumin, 0.05% (v/v) Triton X-100
(pH 7.5)], protein extraction (0 to 10 μg) in a 10 μl reac-
tion volume and were incubated at 37°C for 15minutes.
The reactions were terminated by adding 10 μl formam-
ide with dyes. Equal volumes (20 μL) of the reaction
products from assays of AP endonuclease activity were
resolved in a 20% polyacrylamide gel with 7 M urea in
1 × Tris-borate EDTA buffer at 300 V for 40 minutes.
Wet gels were autoradiographed at −70°C overnight.
Electrophoretic mobility shift assay (EMSA)
EMSA was performed according to the LightShift Chemi-
luminescent EMSA kit user’s instructions with minor
modifications. Briefly, 5 μg of nuclear extracts were incu-
bated with 3′-biotin labeled, purified double-stranded
oligonucleotide probes. The probes containing NF-κB
consensus sites: NF-κBF: 5′-AGTTGAGGGGACTTTCC
CAGGC-3′ and NF-κBR: 5′- CGGACCCTTTCAGGG
GAGTTGA -3'were synthesized and labeled with biotin at
the 3′ end. After incubation for 30 min at room
temperature, samples were separated on a pre-run 5%
polyacrylamide gel at 100 V for 90 min and then trans-
ferred to Zeta-Probe GT nylon membrane (Bio-Rad). The
probes were detected by HRP-conjugated streptavidin
(1:300) and the bands were visualized by ECL reagents
provided with the kit. The resultant bands were quantified
using the imaging software Quantity One (Bio-Rad).
Comet assay
The cells were rinsed twice with ice-cold PBS and har-
vested, and the cell suspension was exposed to melpha-
lan on ice for 15 min. Immediately after treatment or
after a 30 min recovery incubation at 37°C post treat-
ment, the cell suspension was stored on ice and an alka-
line comet assay performed using a Comet assay kit
(Trevigen, USA) according to the manufacturer’s in-
structions with modifications.
Co-immunoprecipitation assay
Cells were harvested by scraping and washed once with
ice-cold phosphate-buffered saline (PBS). Cell pellets
were resuspended and incubated in IP lysis buffer (Beyo-
time Institute of Biotechnology, Jiangsu, China) supple-
mented with protease inhibitor cocktail (Pierce) at a cell
density of 107 cells/ml on ice for 30 min. After centrifu-
gation at 12,000 × g for 10 min at 4°C, the supernatant
was collected as total cell lysate. Protein concentration
was determined by using the Bradford assay (Bio-Rad,
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with protein A/G agarose resin for 30 min on ice then
coimmunoprecipitated for 3 h using APE1 antibody
(Novus) following the manufacturer’s instructions. After
incubation, protein A/G agarose resin was then added
and incubated for 1 hour at 4°C. After washing 3 times
with PBS containing protease inhibitor, the pellet con-
taining agarose beads together with binding proteins
were mixed with sample buffer and incubated at 100°C
for 5 min. The samples were then stored at −80°C or
subjected to Western blotting analysis immediately.
Results
The differential expression of APE1 in RPMI-8226 and
U266 parental cell and their drug-resistant cell lines
RPMI-8226/LR5 and U266/LR6
To investigate the role of APE1 in melphalan resistance
of multiple myeloma cells, we utilized melphalan-
resistant MM cell lines RPMI-8226/LR5 and U266/LR6
and their parental cells. The drug resistant statuses of all
cell lines were validated by CCK-8 assay (Figure 1A).
The results suggested that the proliferation of 8226/LR5
and U266/LR6 cells are slightly inhibited by differentFigure 1 APE1 overexpression in melphalan-resistant MM cell lines RP
8226/LR5 and U266/LR6 show more resistance to melphalan than their par
three different doses of melphalan for 48 hours then cell viability was assay
from three separate experiments. The significance was analyzed by Studen
and RPMI-8226 or between U266/LR6 and U266 are statistically significant (
level was assayed using quantitative RT-PCR and Western blots, respectively
was from three independent experiments. Representative blot images are sdoses of melphalan while the growth of the parental cell
lines are significantly suppressed by the drug (all p
values < 0.01). The differential expression of APE1 was
then measured for both mRNA and protein levels in
these two groups of cell lines by quantitative RT-PCR
and Western blot, respectively. Figure 1B and C show
both APE1 mRNA and protein levels were higher in the
melphalan-resistant cell lines (both p values <0.01) sug-
gesting that APE1 is a melphalan responsive gene. To
check this hypothesis we challenged the cells with
15 μM melphalan for 1 hour then measured APE1 ex-
pression differences in both wildtype RPMI-8226 and
RPMI-8226/LR5 cells. As shown in Figure 2A and B,
APE1 mRNA expression was elevated after melphalan
treatment as early as 3 hours while protein level was ele-
vated at 18 hours after treatment. The peak of APE1
protein elevation was at 24 hours after melphalan treat-
ment and the mRNA peak was at 12 hours. The signifi-
cant elevation of APE1 expression was observed in a
dose dependent fashion at 24 hours post melphalan
treatment (Figure 2C and D). On the other hand, the
APE1 level, which is already high in RPMI-8226/LR5
cells, failed to show a significant increase until high doseMI-8226/LR5 and U266/LR6. (A) CCK-8 assay indicated that RPMI-
ental cell lines RPMI-8226 and U266. All cell lines were treated with
ed using the CCK-8 assay. Results are shown as mean ± SD and were
t t test. Stars (*) represent that the differences between RPMI-8226/LR5
p < 0.01). Differential APE1 expression at the mRNA (B) and protein (C)
. The bar graph showing the quantitative results of APE1 mRNA levels
hown and β-actin was used as a loading control.
Figure 2 APE1 responds to melphalan treatment. Both mRNA and protein levels were elevated after melphalan treatment in a time course in
RPMI-8226 cells. Quantitative PCR results are shown as a bar graph in (A) and representative Western blot images are shown in (B). In addition,
expression of APE1 mRNA (C) and protein (D) levels increased in a melphalan dose dependent manner. (E) APE1 protein level alterations in
melphalan-resistant line RPMI-8226/LR5 were tested by Western blot at different time points post 15 μM melphalan treatment (left panel) or at 24
hours post various doses of melphalan treatment (right panel). All quantitative RT-PCR results were statistically processed from three independent
experiments, and the blot is a representative of three independent Western blots. Stars (*) represent that the difference between the indicated
group and DMSO (vehicle) treated RPMI-8226 is statistically significant (p < 0.01).
Xie et al. BMC Cancer 2014, 14:11 Page 5 of 11
http://www.biomedcentral.com/1471-2407/14/11treatment of melphalan (60 μM). These correlative data
suggested that APE1 could play a role in a melphalan-
induced cellular response and consequently promote re-
sistance to melphalan.
Manipulation of APE1 affects cell resistance to melphalan
To further confirm the role of APE1 in melphalan resist-
ance, we utilized RNAi and vector-based overexpression
strategies to manipulate cellular APE1 expression in
wildtype RPMI-8226 cells. The changes in drug resist-
ance were then observed in cells with exogenously al-
tered APE1 expression. RNAi was performed using
adenovirus previously engineered by our lab and its effi-
cacy was confirmed by Western blot [22]. Both RNAi
and overexpression effectively altered total cellular APE1protein levels at 48 hours after transduction according
to the Western blot shown in Figure 3A. Noteworthy,
since the B cell origin of both parental MM cell lines,
we found that the APE1 knockdown rendered no signifi-
cant growth inhibition under untreated conditions,
which agrees with previous reports [23,24]. The melpha-
lan resistance was then tested by CCK-8 assay in the
groups with different APE1 expression levels. The cell
killing effects by melphalan were measured at 24, 48 and
72 hours after 15 μM melphalan treatment. Figure 3B
clearly indicates that APE1 deficiency sensitized RPMI-
8226 cells to melphalan; meanwhile, overexpression of
APE1 rendered 8226 cells with enhanced resistance to
melphalan. In addition, we also tested if APE1 inhibition
in RPMI-8226/LR5 cells could restore the sensitivity to
Figure 3 Manipulation of APE1 affects cell resistance to melphalan. (A) APE1 protein levels at 48 hours post transfection of siRNA or
overexpression vector in RPMI-8226 cells were measured using Western blot. Transfection reagent only treated cells were included as a control.
(B) Cell survival after 24, 48 and 72 hours post 15 μM melphalan treatment in all three groups was measured using CCK-8 assay. A star (*)
represents that the difference between the shAPE1 transfected group and the vehicle alone group is statistically significant (p < 0.05), # represents
that the difference between pcDNA-wtAPE1 transfected group and vehicle alone group is statistically significant (p < 0.05). (C) APE1 knockdown
in RPMI-8226/LR5 partially restored the sensitivity to melphalan. The results shown in the bar graph indicated the cell viability in different groups
after melphalan treatment using the CCK-8 assay. The representative Western blots show APE1 was effectively knocked down in RPMI-8226/LR5
by siRNA transfection. A star (*) represents that the difference between siAPE1 and vehicle alone transfected RPMI-8226/LR5 is statistically
significant (p < 0.05), # represents that the difference between shAPE1 transfected RPMI-8226/LR5 and vehicle alone transfected RPMI-8226 is
statistically significant (p < 0.05). All results were from three independent experiments.
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levels were effectively downregulated as shown in
Figure 3C. At 48 hours following melphalan treatment,
CCK-8 assays were performed to measure the cell viabil-
ity in different groups. The results indicated that APE1
knockdown significantly decreased RPMI-8226/LR5 sur-
vival under various doses of melphalan treatment (p <
0.01), and it restored the melphalan sensitivity of RPMI-
8226/LR5 to the level of its parental cell line (p > 0.05).DNA repair is involved in melphalan-resistant MM cells
To comparatively investigate the importance of different
functions of APE1 in melphalan resistance of RPMI-
8226, three constructs expressing loss-of-function mu-
tants of APE1 were introduced. Since APE1 is generally
an abundantly expressed protein, we first knocked down
its expression by shAPE1 adenovirus. As shown in a pre-
vious study, the APE1 expression level was suppressed
for more than 96 hours which gave us a window to
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the biological changes. APE1H309N, APE1C65S and
APE1K6R/K7R represent repair activity deficiency, redox
activity deficiency, and acetylation site mutants that were
separately transfected into APE1 at 24 hours post
shAPE1 adenovirus infection in RPMI-8226/LR5 cells.
At 24 hours post transfection, the overall APE1 expres-
sion was measured by Western blot using APE1 anti-
body. As shown in Figure 4A, the expression of the
three mutants together with the wildtype APE1 control
(APE1WT) was basically the same at 24 hours post trans-
fection. Additionally, the exogenously expressed APE1
or its mutants demonstrated the same expression level
or even more than the endogenous APE1 which resulted
in significant biological changes by the exogenous mu-
tants. The AP endonuclease activities of different mu-
tants were tested by oligo incision assay. As shown in
Figure 4B, when normalized to the APE1 protein level,
the H309N mutant demonstrated significant loss of AP
endonuclease activity of APE1, whereas other mutants
demonstrated similar activity to the wildtype cell line.
The sensitivities to melphalan of different groups were
then measured by CCK-8 assay and the results indicated
that the knockdown of APE1 sensitized the RPMI-8226/
LR5 cell to melphalan while APE1WT transfection re-
stored the resistance (Figure 4C). In melphalan un-
treated groups, the expression of different APE1Figure 4 Differential involvement of various APE1 functions in melph
mutants were assayed by Western blot and the results indicated that the e
APE1C65S and APE1K6R/K7R cell lines. (B) The AP endonuclease activities of th
cells were measured by oligo incision assay. The representative image out
APE1 mutant-transfected groups was measured by CCK-8 assay after variou
independent experiments and * represents that the difference between th
(p < 0.01), # represents that the difference between the indicated group an
that the difference between the indicated group and the APE1 H309 groupmutants rendered the same cell survival as wildtype
APE1 expression at the time of 72 h (p > 0.05). When
transfected with APE1H309N, APE1C65S and APE1K6R/K7R,
the melphalan resistance of APE1 knockdown cells was
partially restored to different levels. APE1H309N-transfected
cells with DNA repair activity deficiency were significantly
more sensitive to melphalan compared to APE1WT using
the student t test (p < 0.01). Meanwhile, APE1C65S re-
stored melphalan resistance as much as APE1WT with-
out statistical significance (p > 0.05) and APE1K6R/K7R
restored resistance to a level between APE1C65S and
APE1H309N, but significantly lower than the APE1WT
group (p < 0.05). These results demonstrated that both
DNA repair activity and acetylation modification of
APE1 participate in regulating cell survival after mel-
phalan treatment.
The DNA repair activity of APE1 plays an important role
in melphalan resistance
To further explore the mechanism of the multiple APE1
activities in melphalan resistance, the DNA repair func-
tion of APE1 was analyzed first. When we tested the AP
endonuclease by abasic site-containing oligonucleotide
incision assay, the APE activity was significantly higher
(2.19 ± 0.187 fold, p < 0.01) in RPMI-8226/LR5 cells
compared to parental cells (Figure 5A). The results indi-
cated that the repair activity of APE1 probablyalan-resistanct MM cells. (A) The protein expression levels of APE1
xogenous protein levels were comparable in APE1 WT, APE1H309N,
e whole cell extracts from APE1shRNA and exogenous APE1-expressing
of three experimental repeats was shown. (C) Cell survival of different
s doses of melphalan treatment. All results were from three
e indicated group and the APE1 WT group is statistically significant
d APE1shRNA group is statistically significant (p < 0.01), and & represents
is statistically significant (p < 0.01).
Figure 5 DNA repair activity of APE1 plays a critical role in melphalan resistance of MM cells. (A) The difference in DNA repair activity of
APE1 between RPMI-8226/LR5 and RPMI-8226 cells was analyzed using AP site incision assay. The results indicated that the RPMI-8226/LR5 cells
possess a higher AP endonuclease activity than its parental line. (B) The overall DNA repair activity for single DNA strand breaks was assayed by
the alkaline comet assay. Cell suspensions from both RPMI-8226/LR5 and RPMI-8226 cells were treated with 15 μM melphalan on ice for 20 min,
then the comet assay was performed immediately or after a 30 min repair in culture medium in a 37°C incubator. Representative images
are shown.
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to elevated expression. To verify that the DNA lesions
caused by melphalan were less prominent in melphalan
resistant cells, an alkaline comet assay reflecting base or
small patch DNA lesions was performed. In congruence
with APE activity, DNA lesions induced by melphalan
were repaired effectively in RPMI-8226/LR5 compared
to the parental cells which partially explained the differ-
ential sensitivity to melphalan. The reduced DNA repair
capacity of APE1 rendered more DNA single strand
breaks in RPMI-8226 at 30 min post melphalan treat-
ment when compared to RPMI-8226/LR5 (Figure 5B).
The overall DNA repair capacity of single stand breaks
induced by melphalan further confirmed that the DNA
repair activity of APE1 plays a critical role in melphalan
resistance. Taken together, our results indicated that
APE1 DNA repair activity plays an important role in
melphalan resistance. However, the DNA repair function
mutant still increases the melphalan resistance in the
APE1 knockdown background (Figure 4C), which sug-
gested that acetylation modification of APE1 may also
be involved in melphalan resistance.
MDR1 expression is reduced in APE1 deficient MM cells
We then analyzed the possible mechanism of APE1
acetylation-mediated melphalan resistance in MM cells.
Firstly, we detected the acetylation level of APE1 in mel-
phalan resistant MM cell lines and their wildtype coun-
terparts. As shown in Figure 6A, APE1 acetylation levels
could be detected when APE1 was enriched by immuno-
precipitation. After normalization with pan APE1, its
acetylation level increased in the melphalan-resistant
MM cells RPMI-8226/LR5 and U266/LR6 in response to
melphalan treatment. Due to the importance of MDR1in drug resistance, we then measured differences in the
expression of MDR1 between RPMI-8226-LR5 and its
parental cell line. MDR1 is constitutively expressed to a
higher level in melphalan-resistant MM cells as shown
in Figure 6A. Since a previous study [18] reported that
APE1 plays a critical role in regulation of MDR1 expres-
sion through a novel acetylation modification, we then
postulated that APE1 could be involved in melphalan re-
sistance in MM cells by regulating MDR1 expression.
First we observed that APE1 knockdown and overex-
pression in the RPMI-8226 cells manipulated the MDR1
protein expression level (Figure 6B). We then tested if
the melphalan resistance induced by APE1 overexpres-
sion could be negated by knocking down MDR1 expres-
sion. APE1 wildtype cDNA expression vector and a
vector only control were transfected in parallel into
RPMI-8226 cells. Both of these transfected cell lines
were then transfected with siRNA specifically against
Mdr1. Different groups of cells were then challenged
with melphalan. Forty-eight hours later, the cell viability
was tested by CCK-8 assay. The results indicated that
APE1 overexpression enhanced melphalan resistance in
RPMI-8226 cells, and siMDR1 sensitized RPMI-8226 to
melphalan. However, when siMDR1 was combined with
pcDNA-APE1, siMDR1 reduced cell survival after mel-
phalan treatment. These results suggested APE1 benefits
cell survival after melphalan treatment specifically
through an MDR1-dependent mechanism.
Discussion and conclusion
Despite the adverse side effects caused by alkylating
agents on bone marrow and other normal tissues, mel-
phalan remains one of the most commonly prescribed
chemotherapies in MM patients. As the main treatment
Figure 6 MDR1 expression is aberrant in APE1 acetylation site mutant expressing MM cells. (A) At 2 hours after melphalan treatment,
APE1 was enriched by pulldown and blotted with anti-lysine acetylation antibody. (B) The Western blot showed expression levels of MDR1 in
RPMI-8226/LR5, U266/LR6 and their parental cell lines RPMI-8226 and U266. The representative blots showed that melphalan resistant cells have
higher expression levels of MDR1. (C) MDR1 protein expression was detected by Western blot at 48 hours after APE1 siRNA or pcDNA-APE1 was
transfected into RPMI-8226 cells. MDR1 expression was downregulated after knockdown of APE1 in RPMI-8226 cells, and MDR1 was upregulated
after overexpression of APE1. In addition, APE1 WT or APE1 K6R/K7R was transfected 24 hours after APE1 shRNA infection. 48 hours later, MDR1 levels
were detected by Western blot. (D) MDR1 siRNA was applied to the pcDNA-APE1 transfected RPMI-8226 cells at 48 hours post 15 μM melphalan
treatment, and cell viability was measured by a CCK-8 kit. The results were from three independent experiments.
Xie et al. BMC Cancer 2014, 14:11 Page 9 of 11
http://www.biomedcentral.com/1471-2407/14/11regimen of MM, melphalan greatly affects the outcome
of overall treatment through its therapeutic efficacy.
However, a considerable variation of therapeutic re-
sponse to melphalan is observed clinically. We previously
found that melphalan cytotoxicity closely correlates to the
expression level of the multifunctional gene APE1 [15].
Our present results indicate that APE1 has a higher ex-
pression level in the melphalan resistant cell line RPMI-
8226/LR5 and that expression of APE1 is effectively
induced by melphalan in a dose- and time-dependent
manner. We further employed APE1 knockdown andoverexpression vectors to exogenously manipulate the
APE1 levels in RPMI-8226/LR5 and its parental cell line
RMPI-8226 which affected melphalan cytotoxicity. These
results further reinforced the critical regulatory role of
APE1 in melphalan resistance in different MM cell line
models in accordance with our previous observations.
Subsequently, we determined which functions of APE1
were critical for melphalan resistance by taking advantage
of developed melphalan-resistant MM cell lines and APE1
function-specific mutant expression vectors. By comparing
the different capacities of restoring resistance to APE1-
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mutants, the DNA repair activity and the intact acetylation
residues K6 and K7 were shown to play critical roles in
the development of melphalan resistance of MM cells.
Then we performed mechanistic studies of DNA repair
activity and acetylation modification of APE1 and the im-
pact on melphalan cytotoxicity. Altogether our results
identify the most important functions of APE1 in melpha-
lan resistance of MM cells and shed light on future thera-
peutic strategies targeting specific APE1 functions by
small molecule inhibitors.
As predicted, the DNA repair activity of APE1 plays
the most important part in melphalan resistance.
Melphalan, as a typical alkylation agent, exerts its cancer
cell killing effect through DNA damage. Although the
most cytotoxic lesion caused by melphalan is considered
to be the interstrand crosslinks, the majority of DNA le-
sions are N7G monoadducts (~38%) and N3A monoad-
ducts (~20%) [25] which are also potentially lethal by
blocking DNA replication. DNA base alkylation and oxi-
dative lesions are mainly repaired by BER, so it is plaus-
ible that the abasic site endonuclease activity of APE1
functions as a major mechanism in acquired melphalan
resistance. Although the various single base lesions re-
quire different lesion-specific glycosylases, APE1 is com-
mon to BER and incises the backbone of the DNA strand
and facilitates gap filling by DNA Polβ. Therefore, the ac-
tivity of APE1, essential for BER, determines the repair
capacity of mono methylation induced by alkylation agents
including MMS [14] and melphalan. In addition, DNA re-
pair activity is associated with the sensitivity of different
agents targeting DNA which mainly cause different types
of lesions including cisplatin [13], 5-FU [26], bleomycin,
and ionizing radiation (IR) [27]. Although the detailed
mechanisms of the repair activity of APE1 in drug resist-
ance remain unclear, these observations imply a more im-
portant role of APE1 in promoting cell survival though a
DNA repair-dependent mechanism.
We recently observed that APE1 was highly expressed
in bone marrow stromal cells (BMSCs) in MM patients
compared to the normal donors. This study provided a
plausible explanation to the drug-resistance of MM by
APE1 in that APE1 regulates cytokines, including IL-6
and IL-8, produced in BMSCs through redox regulation
of NF-κB and AP-1 [28]. This study merely focused on
the role of the microenvironment of MM. However, our
present results indicate that the redox activity of APE1
is not involved in acquired melphalan resistance as we
expected. We actually observed the reduction of IL-6/8
mRNA in redox activity deficient cells (data not shown),
and the reduction of IL-6/8 expression has a minor im-
pact on cell survival after melphalan treatment. The
paracrine agents from the BMSCs in the microenviron-
ment of the bone marrow are the major source ofcytokines and growth factors for MM cell survival;
hence, it is probable that the autocrine cytokines from
MM cells have little effect on drug resistance.
Interestingly, we found that APE1 regulates the sensitiv-
ity of MM cells to melphalan by affecting MDR1 expres-
sion. This MDR1 regulatory role of APE1 is exclusively
dependent on the integrity of acetylation sites at K6/K7 as
reported previously [18]. A previous study indicated that
the MDR1 expression level was associated with low intra-
cellular accumulation and low cytotoxicity of melphalan in
different hematopoietic cancer cell lines, including seven
MM cell lines [29]. In accord with our study, the MDR1
inhibitor successfully reversed melphalan resistance in
MDR1 overexpressed HL-60 cells. However, the regulatory
role of APE1 in melphalan sensitivity occurs only partially
through MDR1 expression. As shown in Figure 6, knock-
down of MDR1 in APE1-overexpressed RPMI-8226 cells
only partially restores sensitivity to melphalan compared
to the MDR1 knockdown in RPMI-8226 cells.
In this present study we are the first to identify, to our
knowledge, that the APE1 DNA repair function, together
with acetylation modification, plays the most important
role in melphalan resistance. Although we demonstrated
the critical function of APE1 in melphalan resistance
through cell models in this current project, the detailed
molecular mechanisms in intrinsic resistance to melpha-
lan are still unknown. Since different mechanisms may
be involved in intrinsic and acquired melphalan resist-
ance, more work needs to be done using different cell
models to determine the different functions of APE1 in
intrinsic and acquired melphalan resistance.
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